Creative Deal Structures and Financial Consideration for Life Science Transactions

As capital sources become more scarce companies are increasingly exploring creative methods to structure transactions. This session will focus on unique financial structures that have been utilized in the life sciences industry that include the sharing of assets, risk and capital. As big pharma continues to vary their cost structure, successful transaction structures that build value are likely to gain traction. This panel discussed the following areas:

• An overview on unconventional transaction structures
  
• Opportunities to participate in big pharma’s transformation to a variable cost structure
  
• What part of the FIPCO value chain offers the opportunity to utilize nonconventional transaction structures
  
• What are the overall financial considerations that an investor must always consider
  
• With the credit markets and public markets in the current state of uncertainty does this present unique investment opportunities?

Presenters included:

• John Babitt, Transaction Advisory Services, Ernst & Young LLP
  
• Julia Gregory, Consultant and Formerly Executive Vice President and Chief Financial Officer, Lexicon Pharmaceuticals, Inc.
  
• Derek Lee, Principal, SV Life Sciences
  
• James Murphy, Vice President and Chief Financial Officer, OXiGENE, Inc.